FDA Approves Aimovig (erenumab-aooe) as a Preventive Treatment for Migraine
May 17, 2018 -- The U.S. Food and Drug Administration today approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. The treatment is given by once-monthly self-injections. Aimovig is the first FDA-approved preventive...
Publication date: March–April 2019Source: Brain Stimulation, Volume 12, Issue 2Author(s): Eran Schenker
Publication date: March–April 2019Source: Brain Stimulation, Volume 12, Issue 2Author(s): Gad Alon
BY JORDAN DEMCHUKA 59-year-old Caucasian man with a past medical history of well-controlled hypertension, hyperlipidemia, and gout presented to the ED with altered mental status. His wife reported that he was found two hours earlier in his home office confused, unable to recall plans made that morning, the current time and date, and his brother's death a year and a half earlier. She stated that the patient was repeating, “I don't know what's happening,” while anxiously pacing around the room. She said he had a history of falls and head injury at age 7, which was accompanied by brief amnesia that had not recu...
Migraine headache is one of the most common chronic conditions (Steiner et al. 2013), yet available pharmacologic treatment often entails side effects that many be considered intolerable. About 12 percent of people will experience a migraine headache at some point in life. More than half of migraine sufferers have at least one attack per month. Migraines can dramatically impact work, family, and social life. Estimates place the annual cost of migraines at $14 billion. Medications to treat acute migraine attacks include non-steroidal anti-inflammatory drugs, paracetamol, triptans and anti-nausea medications.
Introduction: This proof of concept study used a novel non-invasive CTO-NS device to assess the efficacy of concurrent Trigeminal and Occipital nerve stimulation compared to stimulation of the trigeminal nerve only, in treatment of migraine headache.
Introduction: Treating patients with failed back surgery syndrome with spinal cord stimulator (SCS) may prove to be difficult in patients with anatomical variations of their spine. These difficulties may lead to inadvertent dural puncture, and potentially post dural puncture headache (PDPH). Patients who develop these complications pose a challenge in determining whether or not to proceed with a SCS trial, and whether or not to proceed with an epidural blood patch (EBP) with SCS leads in situ.
Introduction: In this recent study we have employed a novel type of stimulation, micro-magnetic stimulation ( μMS), for vagus nerve stimulation (VNS). Electrical VNS is commonly used to treat drug-resistant epilepsy, depression, and headache. However, oxidation/reduction reactions at the electrode-tissue interface can result in damage and reduce the efficacy of stimulation, while concerns regarding device and tissue damage prevent patients with VNS implants from receiving the diagnostic benefits of imaging devices such as magnetic resonance imaging (MRI).
We present a case where combined PNS and trigger-point mapped peripheral field stimulation (PFNS) were used in tandem to achieve clinical success.
Children and youth are at a greater risk of concussions than adults, and once injured, take longer to recover. The increased incidence of sports-related concussion/mild traumatic brain injury (mTBI) in youth and the potentially serious long-term negative impact on their developing brains has enormous repercussions. While most young athletes recover within several days, many continue to experience symptoms for many months post-concussion. Symptoms are wide ranging and include – most notably: headache, sleep disturbances, brain fog, irritability as well as impairments in emotion and cognitive function (i.e.
Neuroplasticity in the visual cortex is essential for cognitive functions associated with visual processing. In humans, pathophysiological alterations of visual cortical excitability are observed in migraines. Visual plasticity can be induced via light deprivation or non-invasive brain stimulation protocols over the visual cortex. However, a synapse-specific plasticity, which is suggested as the key component in learning and memory processing, has not been demonstrated in human visual cortex so far.